From the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P).

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P). In the upcoming issues, our editors will develop regular columns on topics ranging from billing & coding problems to legal advice and practice management tips, all of which are designed to give quick-reading, issue-solving information for today’s busy oncologists.

Along with the regular feature departments, we will also report on the broader political actions and initiatives that influence the practice of oncology. To that end, we will continue to build our working relationship with ASCO, ASH, and ACCC to deliver consensus-driven views from leading experts on issues such as the impending work-force shortage of medical and gynecological oncologists, the challenges of implementing HIT, cancer care quality initiatives, and regulatory and advocacy issues.

As always, we encourage our readers to share their thoughts, advice, or opinions about anything that appears on these pages. [Please send comments to: Ronald.Piana@cmpmedica.com.]

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.